Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)

One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. We believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).
In this open label randomised clinical trial, patients with recently symptomatic and severe stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA) with impaired cerebral vasodilatory reserve (CVR) will be included. CVR will be measured with transcranial Doppler (TCD) breath holding index and acetazolamide-challenged single photon emission computed tomography (SPECT). Patients meeting the eligibility criteria would be randomised to receive best medical therapy (according to the international guidelines and institutional practices) or Dulaglutide subcutaneous injection (0.75mg and titrating to 1.5mg, if indicated) once a week, in addition to the best medical therapy. CVR will be measured again at the completion of 1 year. MRI of the brain will be repeated to evaluate any new ischaemic brain lesions. All patients would be followed up for two years for cerebral ischaemic events.
We hypothesize that addition of GLP1 RA therapy would lead to a reduction of at least 4 units in CVR on SPECT as compared to best medical therapy.

Start Date02 Dec 2025

Sponsor / Collaborator

National University of Singapore

NCT06851962

/ Not yet recruitingPhase 4IIT

Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:
* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?
Participants will:
* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Start Date01 Apr 2025

Sponsor / Collaborator-

NCT06739122

/ RecruitingPhase 3

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Start Date10 Jan 2025

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Dulaglutide

100 Translational Medicine associated with Dulaglutide

100 Patents (Medical) associated with Dulaglutide

1,206

Literatures (Medical) associated with Dulaglutide

01 Dec 2025·Journal of Orthopaedics

Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair

Article

Author: Ilyas, Asif M ; Rasmussen, Spencer T

Objectives:

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is increasingly common among orthopaedic patients, often prescribed for type 2 diabetes mellitus and obesity, which are frequent comorbidities. Recent studies have explored the effects of GLP-1's on postoperative outcomes in orthopaedic procedures. This study evaluates the impact of GLP-1 on re-operation risk following rotator cuff repair (RCR).

Methods:

A retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network. Patients with documented RCR and no prior GLP-1 use were included in the control group. Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group. After comparing baseline characteristics, cohorts were matched based on selected covariates. Outcomes were compared using risk ratios (RR) with 95 % confidence intervals (CI). A subgroup analysis by GLP-1 indication (type 2 diabetes or weight loss) was performed.

Results:

Propensity score matching yielded well-balanced cohorts of 5306 patients. Subgroup analysis included 781 patients per group. At 3, 6, and 12 months post-RCR, the control group showed no difference in reoperation risk. In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).

Conclusion:

The use of GLP-1 was not associated with a higher reoperation risk after RCR, suggesting that these medications can safely be taken leading up to RCR. However, increased short-term risks in diabetes patients highlight the need for individualized care and further study of GLP-1 effects on orthopaedic outcomes.

01 Dec 2025·INTERNATIONAL JOURNAL OF CARDIOLOGY

Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis

Review

Author: Ribeiro, Danilo Monteiro ; Said, Thomas Benevides ; de Araujo Paysano, Maria Lúcia Brito ; Matheus, Gustavo Tadeu Freitas Uchôa ; Kelly, Francinny Alves ; Rebelo, Thiago Gorayeb

BACKGROUND:

Cardiovascular disease remains a leading cause of morbidity and mortality in type 2 diabetic mellitus (T2DM) patients. While injectable GLP-1 RAs have demonstrated efficacy in reducing cardiovascular risk, an oral formulation of semaglutide was developed to improve accessibility and treatment adherence, however, its therapeutic potential has yet to be fully elucidated. This meta-analysis evaluates the efficacy of oral semaglutide on cardiovascular outcomes to better inform clinical decision-making.

METHODS:

A systematic search was conducted in major databases for randomized controlled trials (RCTs) up to May 2025, with a primary outcome of cardiovascular events, expanded outcomes included nonfatal stroke, death from cardiovascular cause, and nonfatal myocardial infarction, and the secondary outcome was all-cause mortality. Statistical analysis was performed using RStudio, with heterogeneity assessed via I² statistics.

RESULTS:

A total of 13,875 patients were included, of whom 6935 received oral semaglutide and 6940 received placebo from the 5 eligible studies. A significant difference was observed for cardiovascular events with a risk ratio (RR) of 0.86 (95 % CI: 0.78-0.95; p = 0.0029; I² = 0 %) and hazard ratio (HR) of 0.85 (95 % CI: 0.77-0.95), respectively. In contrast, no significant difference was found for nonfatal stroke, all-cause mortality, death from cardiovascular causes, and nonfatal myocardial infarction.

CONCLUSION:

The meta-analysis revealed that oral semaglutide was cardioprotective in T2DM patients with consistent reductions in cardiovascular event risk. However, the lack of significance in the remaining outcomes underscores the need for further investigation.

01 Dec 2025·Journal of Gynecology Obstetrics and Human Reproduction

Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis

Review

Author: Armstrong, Bruna Benigna Sales ; Martin, Giovanna Cristina de Castro ; Amador, Wellgner Fernandes Oliveira ; Machado, Guilherme Franceschini ; Servidoni, Ana Clara Pimenta ; Yousif, Abdelrahman

OBJECTIVE:

Primary endpoint is maternal and fetal complications during pregnancy, labor, and delivery after exposure to GLP-1 receptor agonists.

DATA SOURCES:

A systematic search was conducted across PubMed, Embase, and Cochrane Central databases, including studies published from 2020 to 2025.

STUDY ELIGIBILITY CRITERIA:

Included studies: (1) RCTs or cohorts; (2) exposure to GLP-1 RAs during pregnancy or preconception; (3) control group not exposed to GLP-1 RAs. Excluded studies: (1) without outcomes of interest; (2) lacking data transparency; (3) retracted; (4) abstracts, case reports, reviews; (5) no control group.

STUDY APPRAISAL AND SYNTHESIS METHODS:

Six studies evaluated GLP-1 RA exposure during preconception or first trimester. Two authors screened studies; a third resolved disagreements. Risk of bias was assessed with ROBINS-I and RoB 2. Meta-analysis pooled continuous outcomes with mean differences and binary outcomes with odds ratios. Heterogeneity was evaluated via Cochrane Q and I². Subgroup analysis focused on first-trimester exposure.

RESULTS:

No statistically significant differences in pregnancy outcomes between GLP-1 RA and control group, including fetal growth restriction or small for gestational age (p = 0.12), live births (p = 0.10), major birth defects (p = 0.79), miscarriages (p = 0.41), preterm delivery (p = 0.62); and stillbirths (p = 0.09). GLP-1 RAs were linked to a lower risk of congenital heart defects (p = 0.03), even in the subgroup analysis (p = 0.03), and showed no significant protective effect against gestational diabetes (p = 0.49). In subgroup analysis, there were no notable differences in miscarriage (p = 0.32), major birth defects (p = 0.83) and preterm delivery (p = 0.88); there were fewer live births that did not reach statistical significance (p = 0.06).

CONCLUSION:

No statistically significant difference was observed between the control and intervention groups. GLP-1 RAs were connected to a lower risk of congenital heart defects.

472

News (Medical) associated with Dulaglutide

13 Dec 2025

·www.sciencedaily.com

Ozempic may offer a surprising bonus benefit for brain health

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous long-term studies are needed to understand the link.Highlights Early research suggests a possible connection between GLP-1 drugs and epilepsy risk A preliminary study involving people with diabetes has found a possible link between the use of glucose-lowering GLP-1 drugs and a reduced chance of developing epilepsy. The findings were released on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology. GLP-1 drugs, known scientifically as glucagon-like peptide-1 receptor agonists, are commonly used to manage diabetes and support weight loss. The study does not prove that GLP-1 drugs lower the risk of developing epilepsy; it only shows an association. "Additional randomized, controlled trials that follow people over time are needed to confirm these findings, but these results are promising, since people with diabetes are at increased risk for developing epilepsy later in life," said study author Edy Kornelius, MD, PhD, of Chung Shan Medical University in Taichung, Taiwan. "Epilepsy can have many physical, psychological and social consequences, and many people do not respond to the current medications, so finding ways to reduce this risk is critical." How researchers compared GLP-1 drugs with other diabetes medications To explore this potential relationship, researchers reviewed data from a U.S. health database that included adults with type 2 diabetes. These individuals had begun treatment with either a GLP-1 drug or a different type of diabetes medication called a dipeptidyl peptidase-4 inhibitor (known as DPP-4 inhibitors or gliptins). None of the participants had a prior diagnosis of epilepsy or seizure. The GLP-1 medications included dulaglutide, liraglutide and semaglutide. The study followed 452,766 people with an average age of 61. Half of them were prescribed GLP-1 drugs, and the other half received DPP-4 inhibitors. Each person was monitored for at least five years. During that time, 1,670 people using GLP-1 medications developed epilepsy, or 2.35%, compared with 1,886 people taking DPP-4 inhibitors, or 2.41%. Adjusted results show a modest reduction in epilepsy risk After the researchers accounted for other health conditions that might influence epilepsy risk, including age, high blood pressure and cardiovascular disease, they found that people taking GLP-1 drugs were 16% less likely to develop epilepsy than people using DPP-4 inhibitors. When the team evaluated the individual GLP-1 medications, semaglutide showed the strongest association with a lower epilepsy risk. "More research is needed, but these findings support the theory that GLP-1 drugs may have neurological benefits beyond controlling blood sugar," Kornelius said. "It should be noted that these findings do not imply that DPP-4 inhibitors are harmful in any way or that GLP-1 drugs are definitely beneficial for brain health." Additional considerations and study limitations Kornelius also noted that tirzepatide, a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, was not part of the analysis because it became available after the study period began. As a result, the findings may not apply to tirzepatide. In addition to the limitations of the retrospective, observational design, researchers lacked information on several other factors that might influence epilepsy risk, such as family medical history, genetic susceptibility or alcohol use. It is also possible that cost, insurance requirements or the severity of a person's diabetes played a role in which medication they were prescribed, which could create differences between the groups that were not fully captured. The study was supported by Chung Shan Medical University Hospital.

Clinical Result

27 Nov 2025

·www.prnewswire.com

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to maintain the achieved weight loss and improved long-term adherence. This phase 3 study (Chinadrugtrials.org.cn: CTR20254659) is designed to evaluate the efficacy and safety of once-monthly bofanglutide injection on body weight after 24 weeks of continuous treatment. Professor Linong Ji from Peking University People's Hospital is the leading principal investigator of the study. The primary endpoints were the change and the percentage change from baseline in body weight at Week 24. Previously, Gan & Lee has conducted two phase 3 clinical studies (GRADUAL-1 and GRADUAL-2) of bofanglutide injection for weight management in adults with obesity or overweight. In GRADUAL-2 study, bofanglutide injection is the first GLP-1 RA globally to be evaluated in a head-to-head, parallel-group comparison with semaglutide 2.4 mg (Wegovy®) in Chinese adults with obesity or overweight, with or without type 2 diabetes. These studies are designed to comprehensively assess and confirm the efficacy and safety of bofanglutide injection in patients with obesity or overweight, as well as its overall impact on metabolic parameters and cardiovascular risk factors. The GRADUAL-3 clinical study will further explore the potential of once-monthly bofanglutide injection to maintain the achieved weight loss and improved long-term adherence. By reducing injection frequency and offering a more convenient treatment regimen, GRADUAL-3 is expected to support long-term treatment adherence and address key challenges associated with GLP-1 RA therapy, including weight regain and suboptimal durability of weight-loss efficacy over time. GRADUAL Clinical Development Program The GRADUAL clinical development program of bofanglutide injection is designed to comprehensively evaluate its efficacy and safety in adults with overweight or obesity. Three large-scale phase 3 clinical studies are currently ongoing in China, with a planned total enrollment of more than 1,000 participants. GRADUAL-1 is a 52-week, phase 3 clinical study in approximately 630 Chinese adults with obesity or overweight who have not achieved adequate weight loss with diet and exercise, evaluating the weight-loss efficacy and safety of bofanglutide injection. GRADUAL-2 is a 52-week, phase 3 clinical study in approximately 471 Chinese adults with obesity or overweight who have not achieved adequate weight loss with diet and exercise, with or without type 2 diabetes, assessing the weight-loss efficacy and safety of bofanglutide injection compared with Wegovy ® (semaglutide 2.4 mg, for weight management). GRADUAL-3 is a 24-week, phase 3 clinical study designed to explore the efficacy and safety of once-monthly bofanglutide injection on maintaining weight-loss effect. Bofanglutide injection Bofanglutide injection (research code: GZR18) is a novel GLP-1 RA developed by Gan & Lee Pharmaceuticals. Its clinical development currently focuses on two indications: obesity/overweight and type 2 diabetes. Bofanglutide injection has demonstrated outstanding weight-loss and glucose-lowering effects in clinical studies, while also providing comprehensive metabolic benefits. The overall safety and tolerability profile of bofanglutide is consistent with that of marketed GLP-1 RAs. Currently, the global development of bofanglutide has advanced to the phase 3 stage. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. SOURCE Gan & Lee Pharmaceuticals 21% more press release views with Request a Demo

Phase 3

21 Nov 2025

·www.sciencedaily.com

New evidence shows tirzepatide and semaglutide strongly protect the heart

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs.A research team at Mass General Brigham has released new evidence directly comparing how well tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) protect the heart. According to the analysis, both medications lowered the chances of heart attack, stroke, and death from any cause. The study appears in Nature Medicine, and the findings were also presented at the American Heart Association Scientific Sessions 2025. Earlier studies had already shown that semaglutide lowers the likelihood of major cardiovascular events such as heart attacks and strokes. What had remained uncertain was whether tirzepatide, another widely used treatment for type 2 diabetes, offers similar protection. Large Real-World Dataset Offers New Clarity To investigate this, researchers examined national health insurance claims and compared cardiovascular outcomes among nearly one million adults using tirzepatide, semaglutide, or other type 2 diabetes therapies. "Randomized controlled trials are often considered the reference standard in the medical evidence generation process. However, not all questions can be answered using this time- and resource-intensive method," said first author Nils Krüger, MD, a research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Mass General Brigham Department of Medicine. "Data generated in clinical practice and used secondarily for research allow us to address a wide range of clinically relevant questions time- and resource-effectively -- when applied correctly. Moreover, we can study patients who reflect the reality of everyday clinical care, in contrast to the highly selected participants of randomized experiments." Risk Reductions Seen in Both Medications The results showed measurable cardiovascular benefits among people with type 2 diabetes who were at higher risk for heart-related complications. When compared with sitagliptin, a diabetes medication known to have a neutral effect on cardiovascular outcomes, semaglutide lowered the combined risk of heart attack and stroke by 18 percent. Tirzepatide produced a 13 percent reduction in the risk of heart attack, stroke, and death when compared with dulaglutide, another GLP-1 receptor agonist that has been on the market for many years. "Both drugs show strong cardioprotective effects. Our data also indicate that these benefits occur early, suggesting that their protective mechanisms go beyond weight loss alone," said Krüger. Although the study highlights strong results, the biological pathways behind these heart-protective effects are still not fully understood. Head-to-Head Comparisons Show Only Small Differences Since these medications are relatively new, scientists continue to investigate how they protect the heart, especially in studies that directly compare tirzepatide and semaglutide. Krüger noted that "According to recently presented database analyses by the respective manufacturers, each company's own drug appears to reduce cardiovascular risk much more effectively than the competitor's." He added, "However, our study found only small differences between tirzepatide and semaglutide in cardiovascular protection among populations at risk of adverse events, underscoring that both agents provide protective benefit and could be integrated into clinical cardiovascular practice." "We hope that our study will help clinicians better understand how these new medications work in clinical practice. Our transparent and open science practices, including pre-registration of a public protocol and shared analytic code, are designed to support scientific discussion," said last author Shirley Wang, PhD, an associate epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Mass General Brigham Department of Medicine. Authorship: In addition to Krüger, Mass General Brigham authors include Sebastian Schneeweiss, Rishi J. Desai, Sushama Kattinakere Sreedhara, Anna R. Kehoe, Kenshiro Fuse, Georg Hahn, and Shirley V. Wang. Additional authors include Heribert Schunkert. Disclosures: Schneeweiss reported personal fees from Aetion Inc, a software-enabled analytics company, and grants from Bayer, UCB, and Boehringer Ingelheim to Brigham and Women's Hospital outside the submitted work. Schunkert reported personal fees from AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, MSD, Novartis, Pharmacosmos, Sanofi, Servier, Synlab, Amgen, and Amarin outside the submitted work. Wang reported personal fees from MITRE, a federally funded research and development center for the Centers for Medicare & Medicaid Services and personal fees from Cytel Inc during the conduct of the study. No other disclosures were reported. Funding: This work was funded by the National Institutes of Health (R01-HL141505, R01-AR080194) and the German Heart Foundation (S/02/24, SRF-HF/24).

AHAClinical Study

100 Deals associated with Dulaglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Argentina	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Australia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Brazil	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Bulgaria	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Canada	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Chile	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Colombia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Czechia	Eli Lilly & Co.	22 Jul 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	tbcksvngpp(rpvcmuokwv) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation duiiwcatfd (dnmruaxowo )	-	10 Oct 2025
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	ypwrpirekb(dttpuhfygy) = eqrcnnsqlu aypjzbsdjx (acsjivanmv ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	ypwrpirekb(dttpuhfygy) = egfxvxmylm aypjzbsdjx (acsjivanmv ) View more
NCT04255433 (SURPASS-CVOT, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,299	Mounjaro (tirzepatide)	tlwvozpngk(hmitremzxb): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more	Non-inferior	31 Jul 2025
				Trulicity (dulaglutide)
NCT04255433 (SURPASS-CVOT, ADA 12025 \| ADA 22025) Manual	Phase 3	Diabetes Mellitus, Type 2	15,775	Tirzepatide (overall cohort)	pgfypqnens(kalhnugbfi) = whjpmntuqp vkodokbzau (vsjcuislmn )	Positive	20 Jun 2025
				Dulaglutide (overall cohort)	pgfypqnens(kalhnugbfi) = wayglvetdf vkodokbzau (vsjcuislmn )
ADA2025	Not Applicable	Diabetes Mellitus, Type 2	173	Dulaglutide	qjrofjauxw(qcetmcgwsq) = Individual GLP-1RA were associated with an increased risk of GI adverse events compared with SGLT-2i. itojcxpwyh (mmnogsuuhu ) View more	Positive	20 Jun 2025
				Semaglutide
NCT05659537 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	212	Dulaglutide	atfaymmhgf = klehdyozfe fqcnmmcoep (qjmgjhrjay, qbqfjctxoj - gguvtoutig) View more	-	05 Feb 2025
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	eqgcsmtlld(izgrhczdww) = niufvnxdhk xdcishvoos (hiwtlxwgkr )	Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer	50	Durvalumab plus gemcitabine and cisplatin	tppghzkuzc(pevazwtidr) = Most AEs were related to chemotherapy, there were 10% immune related AEs fthvjfrtpe (rujxkrncfa )	Positive	23 Jan 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Durvalumab plus chemotherapy	tnlublrlbr(mswuxfacad) = snvujtfkgp ffjcxewuzx (loqyqahmhd )	Positive	23 Jan 2025
				Chemotherapy only	tnlublrlbr(mswuxfacad) = ijyrfuxhvv ffjcxewuzx (loqyqahmhd )
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Lenvatinib + Gemcitabine-based chemotherapy	jyslfibvwk(tryrtbzctx) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs dwqfzfoahm (xqydyorenk )	Positive	23 Jan 2025
				Durvalumab + Gemcitabine-based chemotherapy

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis